Thank you Obelix for your assistance, pretty sure you are onto it regards the relationships between Bene, Par and Siegfried. In addition, regards the Phase 3 trials I am interested to learn about the design of the trial, what are the End Points, goals and differences in reference to the recent results of the Phase 2B trial secondary Endpoints? A google search of Phase trials broadly indicates to me that Paradigm have already largely accumulated much of the Phase 3 trial data requirements in their Phase 2B results? It appears to me that Phase 3 is mainly about proving the drug works across more patients and across more diverse populations across the world? It also appears to me that there really isn’t much left to prove unless there is a distinctive difference between that Phase 2B and THIS NEXT STEP for Phase 3. Appreciate if anyone can shed some light on the above question as at this juncture it appears to me as very relevant information that not only I would appreciate?
PAR Price at posting:
$1.40 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)